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CHAPTER 5
Regulatory framework 
of genome editing in 
Brazil and worldwide
Introduction
The regulation of the use of products obtained through genome-editing 
techniques has been the subject of great debate worldwide. Currently, the 
discussions are mainly focused on whether products obtained by different strategies 
of site-directed nucleases (SDN) should or not be classified as Genetically Modified 
Organisms (GMOs). 
In the SDN-1 application, the natural DNA cell repair pathway (Non-Homologous 
End-Joining - NHEJ) is explored to introduce simple random mutations (substitutions, 
insertions, and deletions) by systems such as CRISPR-Cas, TALENs, or Zinc Fingers 
Nucleases, which cause silencing of the gene product after breaking DNA (by 
Double-Strand Break - DSB).
In the SDN-2 approach, a template DNA is also used to introduce a change in the 
sequence of nitrogen bases (A, C, G, T) at the target site where the DSB occurred, 
exploring another natural repair system directed by a DNA fragment from the same 
species (Homology-Directed Repair - HDR).
In the SDN-3 approach, both NHEJ and HDR can be explored to insert one or more 
DNA fragments with sequences necessary for the expression of a gene (promoter, 
coding, and terminator region) at a specific location in the genome.
In the following topics, questions related to genome editing regulation in 
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Regulation of gene editing in South America
Brazil 
The total area in the world cultivated with genetically modified (GM) crops 
has increased a thousand times over the past two decades, from a few thousand 
hectares in 1996 to more than 190.4 Mha in 2019 (ISAAA, 2019). Among the countries 
producing transgenic crops, Brazil has the second-largest agricultural area, with 
more than 51.3 Mha, surpassed only by the USA, with 75 Mha. In the 2018/2019 
crop season, over 95% of soybean fields were planted with GM cultivars; for corn, 
over 88% (first and second crop seasons), and for cotton, it reached over 84% of the 
total area (ISAAA, 2019). 
Like many other plant breeding techniques, the use of GMOs in agriculture has 
become important for the production of food and plant by-products. However, 
unlike other technologies, the regulatory framework for GMOs is based on a broad 
list of requirements for risk assessment, which often differ from country to country. 
These requirements are primarily intended to protect human health, animal and 
environmental protection from possible adverse effects of the GMO. However, in 
many cases, such requirements are not proportional to the risks which results in a 
costly and time-consuming process. As an unintended outcome, due to the high 
costs of deregulation, only a few large multinational companies (currently BASF, 
Bayer, Corteva, and Syngenta) have adequate resources to deregulate new GM crops, 
whereas publicly funded research institutions, small and medium-sized companies, 
and universities are generally unable to develop a product that reaches the market. 
Even though they could benefit a broader range of stakeholders, particularly in 
poor regions, many socially beneficial technologies have been discontinued due to 
the regulatory limbo created by the GMO controversy. 
However, after more than two decades of experience, without significant impact 
on human, animal, or environmental health, regulatory agencies are developing a 
more effective regulatory framework for emerging technologies, such as genome 
editing techniques and topical interfering RNA. Thus, allowing acceleration in 
the democratization of biotechnology in agriculture, making it more sustainable, 
guaranteeing food security, maintaining biosafety and economic, social, and 
environmental balance. 
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Brazilian legislation on GMOs
In Brazil, the Biosafety Law (Law No. 11,105, March 24, 2005) was an important 
regulatory mark establishing the safety norms and inspection mechanisms for 
activities involving GMOs and their by-products. This law, regulated by Decree No. 
5.591, of November 22, 2005, was a comprehensive and complementary revision 
to a previous biosafety law (Law No. 8974, May 1, 1995), which was issued mainly 
to regulate the first commercial planting of glyphosate-resistant GM soybean in 
1998. Besides determining the general rules for research and commercial activities 
with GMOs, the Biosafety Law regulates principles and establishes safety standards 
and mechanisms for monitoring activities involving GMOs and their by-products. 
The principles used to draft this law encouraged scientific advances in the areas 
of biosafety and biotechnology, life protection, human health, animal and plant 
health, as well as compliance with the precautionary principle for environmental 
protection. The Biosafety Law also established the National Biosafety Council 
(CNBS – in Portuguese Conselho Nacional de Biossegurança). In addition, as foreseen 
by the Biosafety Law, the National Technical Biosafety Commission (CTNBio – in 
Portuguese Comissão Técnica National de Biossegurança) was created to support the 
Federal Government in the establishment of the National Biosafety Policy. CTNBio 
is also responsible for issuing normative resolutions and instruction supporting the 
technological development of the sector with legal assurance and biosafety.
The objective and scope of the Biosafety Law is to provide safety standards 
and inspection mechanisms for construction, cultivation, production, handling, 
transportation, transfer, import, export, storage, research, environmental release, 
unloading, and commercialization of GMOs and their by-products. The law covers 
research activities and commercial uses of products developed for agriculture, 
human and animal health, the environment, and fishing. Anyone interested in 
carrying out one of these activities must request permission to CTNBio, which will 
respond within the deadline stipulated in the Normative Resolutions. All public and 
private organizations, national or foreign, that want to carry out activities or projects 
in Brazil, must request the Certificate of Quality in Biosafety (CQB - in Portuguese 
Certificado de Qualidade em Biossegurança) issued by CTNBio before starting any 
activity. CTNBio, through its Normative Resolutions, is responsible for establishing 
the biosafety guidelines for matters within its competence. Among its prerogatives, 
the law delegates to CTNBio the assessment of new technologies and their possible 
impacts on the environment, human and animal health in the country. If necessary, 
CTNBio may also propose regulations for these new technologies.
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Regulation of new breeding technologies in Brazil 
For any new technology, such as CRISPR (Clustered Regularly Interspaced Short 
Palindromic Repeats), it is essential to guarantee its safety. However, to allow 
technological advancement, all safety requirements must be proportional to the risk. 
When the Biosafety Law was issued, most of the Innovative Precision Improvement 
Techniques (TIMP - in Portuguese Técnicas Inovadoras de Melhoramento de Precisão), 
also known as New Breeding Technologies (NBTs) were still at an early stage and, at 
the time, were not considered.
Thus, in 2015, CTNBio established a task force of experts among its members to 
analyze the products of the new breeding techniques and define how these products 
should be included in the definitions of the Biosafety Law, and propose improvements 
in the current regulations. The techniques analyzed by the task force included gene 
editing, early flowering, reverse breeding, interfering RNA, oligonucleotide-directed 
mutagenesis, among others. For most products and technologies considered by 
the task force, the use of NBTs can accelerate the introduction of traits of interest in 
elite genotypes in breeding programs. In many situations, the final product could be 
classified as non-genetically modified (non-GM) for legislation purposes. 
Several products obtained by editing genes result in genetic modifications 
that could be obtained by established mutation techniques, such as radiation 
and chemical mutagenesis. As the Brazilian Biosafety Law considers organisms 
obtained by mutagenesis methods as non-GM, the task force considered that, after 
a case-by-case analysis, some products could be excluded from the scope of the 
legislation on GMOs. CTNBio Normative Resolution No. 16 (RN16), proposing an 
updated NBTs regulation, was drafted based on the report of the task force and 
regulations and experiences of other countries. The RN16 draft was unanimously 
approved by the members of CTNBio and by the Legal Counsel of the Ministry of 
Science, Technology, and Innovations, and published in the Federal Official Gazette 
on January 15, 2018. 
In general terms, the principle of RN16 is to determine, through a case-by-case 
consultation system, whether a product generated by NBTs should or not be classified 
as GMO by CTNBio (Figure 1). For this consultation, the developer institution must 
provide information about the original organism and the product, including the 
methods used to generate it, and its molecular analysis. The classification of a 
product as non-GMO (for legislation purposes) is based on the following criteria: 
(I) absence of recombinant DNA/RNA; (II) presence of genetic elements that could 
be obtained by crossing; (III) presence of induced mutations that could also be 
obtained by established techniques, such as exposure to radiation or chemicals; 
and (IV) the presence of mutations that could occur naturally.
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In practical terms, products obtained by random mutation directed to the site 
that involves the junction of non-homologous ends (SDN1 mutation) or homologous 
repair directed to the site that involves few nucleotides (SDN2 mutation) and that 
meet the conditions established in RN16, could be designated as non-GMO, in a case-
by-case analysis. In contrast, transgene inserts targeted to the site (SDN3 mutation) 
will normally be classified as GMO, in a case-by-case analysis, according to the RN16. 
If the product is designated as GMO, the developer must comply with all biosafety 
requirements and will be approved only after CTNBio's risk assessment. If the product 
is not classified as a GMO, it can be registered using existing procedures.
RN16 applies to all types of organisms, including plants, animals, and 
microorganisms, in the research and/or commercial release phase. 
Brazilian regulatory framework
The Biosafety Law established a structure with four main organizations 
responsible for risk assessment, and management (Figure 1): (1) National Biosafety 
Council (CNBS), (2) National Technical Biosafety Commission (CTNBio), (3) Local 
Biosafety Committee (in Portuguese CIBio – Comissão Interna de Biossegurança) 
and (4) Registration and Inspection Organizations and Entities (in Portuguese 
OERF - Órgãos e Entidades de Registro e Fiscalização), which includes the Ministry of 
Agriculture, Livestock and Supply (MAPA); the Ministry of Health (MS), the Ministry 
of the Environment (MMA), and the Secretariat of Aquaculture and Fisheries.
The Institutions that intend to work with GMOs must establish a Local Biosafety 
Committee (CIBio) and request a Certificate of Quality in Biosafety (CQB) to CTNBio. 
The CQB is issued after analysis by CTNBio that authorizes the institution to carry 
out activities with GMOs in its facilities, considering that the required safety 
standards are met. After the approval of the CQB, any demand for commercial 
activity with GMOs must be submitted to CTNBio by the CIBio’s president of the 
institution. For a commercial release request, a complete and detailed dossier with 
all biosafety risk assessments must also be included in the process. The guidelines 
for risk assessment are established in Normative Resolution No. 24, of January 7, 
2020, which provides the regulation for the commercial release of GMOs and their 
derivatives. CTNBio evaluates the risk and prepares a technical report. If the GMO is 
approved for commercial release, it is forwarded to CNBS.
National Biosafety Council (CNBS – Conselho Nacional de Biossegurança)
CNBS is a collegiate body composed of eleven high representatives of the State, 
including the Chief of Staff of the Presidency, who presides over it; Minister of 
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Justice; Minister of Science, Technology and Innovations; Minister of Agricultural 
Development; Minister of Agriculture, Livestock and Supply; Minister of Health; 
Minister of the Environment; Minister of Development, Industry and Foreign Trade; 
Minister of Foreign Affairs; Minister of Defense, and the Secretary of Aquaculture 
and Fisheries.
CNBS provides advisory assistance to the President of the Republic in the 
formulation and implementation of the National Biosafety Policy, establishing 
principles and guidelines that consider socio-economic and political conveniences, 
and opportunities of national interest involved in the commercial use of GMOs 
and related products. The CNBS technical opinion on a final decision to release 
a GMO for commercial use will only be requested if socio-economic and/or 
strategic policy decisions are required. Technical judgment on the biosafety of 
a commercially used GMO is under CTNBio’s responsibility. However, CNBS has 
30 days to refute the commercial approval of a GMO after CTNBio has released 
its official position. If the refutation does not occur within 30 days, the product is 
automatically authorized for sale.
National Technical Biosafety Commission (Comissão Técnica Nacional de 
Biossegurança - CTNBio)
CTNBio, linked to the Ministry of Science, Technology, and Innovations (MCTI – 
in Portuguese Ministério da Ciência, Tecnologia e Inovações), is a multidisciplinary 
advisory and deliberative collegiate that provides assistance and technical support 
to the federal government to formulate, update, and implement the National 
Biosafety Policy for the development of GMO products or biotechnology products 
that at some stage could generate a GMO. CTNBio also establishes technical safety 
standards regarding the authorization of activities related to research, and the 
commercial release of GMOs. In addition, CTNBio is responsible for zoo-sanitary, 
phytosanitary, human health, and environmental risks assessment of GMOs, and 
also establishes risk management measures. Other competencies of CTNBio include 
authorizing the importation of GMOs for research, providing technical assistance to 
registration and inspection organizations, and monitoring the development and 
technical-scientific progress achieved in biosafety, biotechnology, bioethics, and 
related areas, with the aim to increase the capacity of protecting human, animal 
and plant health, and the environment.
CTNBio is organized into permanent sectoral sub-commissions in the areas of plant 
and environment, human, and animal health. The president of CTNBio is appointed 
by the MCTI Minister for a 2-year term, extendable for the same period. CTNBio has a 
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permanent executive secretariat that provides technical and administrative assistance 
and organizes monthly meetings (except in January and July).
CTNBio consists of 27 full members and their substitutes, who are also appointed 
by the MCTI minister after receiving nominations from other Ministries. All members 
have a two-year term, renewable for two consecutive terms. They must be Brazilian 
citizens with recognized technical competence and outstanding participation in the 
scientific community. All members must have a doctorate, and be professionally 
active in the areas of biosafety, biotechnology, biology, microbiology, health and 
environment, human/animal health, or related areas. Twelve members of the scientific 
community are directly appointed by the MCTI, while the others are appointed by 
one of the bodies of the CNBS: Ministry of Agriculture, Livestock, and Supply; Ministry 
of Health; Ministry of the Environment; Ministry of Agricultural Development; 
Ministry of Development, Industry and Foreign Trade; Defense Ministry; Secretariat 
of Aquaculture and Fisheries; Ministry of Foreign Affairs, and Ministry of Justice. The 
complete list of CTNBio’s members can be found on its website.
CTNBio meetings can be held with the 14-member quorum (half plus one), 
including at least one representative from each of the four subcommittees. If 
necessary, representatives of the scientific community, the public sector, and civil 
society entities with experience in a specific field may be invited to attend meetings, 
but they are not entitled to vote. Any decision taken by CTNBio must be approved 
by a majority vote. To provide greater transparency to the process, all decisions are 
published in the official journal and open for public comment within 30 days, in 
the same way, that all meetings are open to citizens, who can consult the agendas, 
as well as all documents produced by the commission, which are available on the 
CTNBio’s website1.
Local Biosafety Committee (Comissão Interna de Biossegurança - CIBio)
Any public or private institution that uses genetic engineering techniques 
and methods to develop biotechnological products, which at some stage of 
development can generate a GMO, must have a CIBio, composed of individuals 
with adequate training and education in the areas of biotechnology, genetic 
engineering, biosafety or other related fields. The Biosafety Quality Certificate, a 
document necessary for CIBio to work under government control, is also issued by 
CTNBio to the institution in question.
1  Available at http://ctnbio.mctic.gov.br
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As a mandatory procedure, a researcher must be appointed as responsible for 
each project involving GMOs in the institution. Also, each CIBio is legally responsible 
for ensuring the biosafety conditions of the entity's facilities, conducting regular 
inspections, and sending an annual report of its activities and projects to CTNBio. 
Currently, CTNBio supervises 480 public and private institutions in Brazil.
Registration and Inspection Organizations and Entities (Órgãos e Entidades 
de Registro e Fiscalização - OERF)
The OERF include the Ministry of Agriculture, Livestock, and Supply; Ministry of 
Health; Ministry of Environment, and Secretariat of Aquaculture and Fisheries.
Per Law No. 11,105 and within its field of competence, in compliance with CTNBio's 
resolutions and technical opinions, OERF is responsible for monitoring GMOs and 
their by-products. Its responsibilities include: (1) inspecting research activities, (2) 
registering and inspecting the commercial use of GMOs, (3) authorization to import 
products for research and commercial use, (4) maintaining up-to-date information 
on institutions and researchers who carry out activities and projects; (5) assist 
CTNBio in defining parameters for assessing biosafety; (6) disclosing to the public, 
grant registrations and authorizations for commercial use of GMOs; and (7) enforce 
the law and apply the penalties established when a non-compliance is identified.
Figure 1. The workflow of the general process of approval and commercial release of products generated by NBT, according to 
the Brazilian Biosafety Law nº 11,105/2005 and Normative Resolution nº 16. Caption: 1) Local Biosafety Committee; 2) Biosafety 
Quality Certificate; 3) National Technical Commission on Biosafety; 4) Detailed dossier, with biosafety risk assessments; 5) 
Extendable for an equal period; 6) Genetically Modified Organism; 7) Registration and Inspection Organizations and Entities; 8) 
National Biosafety Council. 
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Overview of the status of biotechnology in Brazilian agriculture
Brazil is one of the main producers of agricultural goods in the world and one 
of the few countries that could considerably increase its production in the coming 
decades, without compromising environmentally protected areas, including the 
Amazon rainforest. In addition, Brazil also has great potential to become the main 
supplier of biofuels. Unlike most developed countries, where bioenergy production 
could compete with food production, Brazil could grow more than 30 Mha without 
destroying native and preserved environments or invading food production 
areas (Malingreau et al., 2012). Also, Brazil contains between 15% and 20% of 
global biodiversity, which has enormous potential as a source of new products for 
agriculture, medicine, and industry.
The Brazilian agriculture (from small to large farmers) and all the agribusiness 
related to it have all the conditions to increase their development at levels similar to 
those of other emerging economies and, consequently, help in the economic and 
social progress of the country contributing to feeding the growing world population. 
In the 1970s, the agricultural and livestock production flow to the Cerrado areas in 
the Midwest Region revealed how agribusiness can improve economic and social 
development. Some cities in the Midwest, for example, currently have the highest 
human development index in Brazil.
Many important achievements of Brazilian agriculture in recent decades resulted 
from the combined application of biotechnological and genetic improvement 
approaches. The combination of these methodologies is crucial to guarantee 
sustainable food production, in a scenario with multiple challenges resulting from 
climatic changes and a growing world population. Thus, to maintain productivity, 
it is essential to be alert, informed, and familiar with new technologies that could 
change concepts and paradigms of production and consumption. 
In December 2018, CTNBio evaluated the first consultation on the commercial 
release of plants generated using NBTs in Brazil. A corn genotype in which the 
metabolic pathway for amylose production was knocked down by CRISPR/Cas9 
was classified as non-GM. After analysis, CTNBio concluded that the mutation 
could have been obtained by conventional breeding methods or induced by other 
mutagens, such as ionizing radiation or by chemical agents. In this specific case, 
the reduction in amylose production resulted in almost 100% amylopectin content, 
which is interesting for some industrial uses of corn starch.
In another consultation, also in 2018, an edited yeast strain (Saccharomyces 
cerevisiae) called “Excellomol” with point polymorphisms introduced in specific 
genes was submitted. Excellomol increased the production of ethanol from 
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sugarcane. Such polymorphisms already occur naturally in the CBS 6412 strain of 
S. cerevisiae, originally identified in the production of sake. Since these mutations 
could have been introduced by other methods of mutagenesis the edited yeast was 
classified as non-GM.
Until March 2020, there were ten consultations since the approval of RN16. Five 
lines of microorganisms (Saccharomyces cerevisiae) for bioethanol production, 
hornless cow (for handling dairy cow), tilapia for improved fillet yield, waxy corn 
for starch quality, a vaccine for canine parvovirus control, and RNAi for the topical 
application to mosquito control. According to the provisions of the RN16, all these 
products, except the hornless cow, were considered by CTNBio as non-GMO. The 
development of NBTs evaluated by modern regulations that protect human and 
animal health and the environment will allow the democratization of biotechnology 
in Brazilian agribusiness. In this context, small, medium, and large national and 
international institutions could participate in the Brazilian and worldwide market, 
developing and introducing new solutions and products through a more sustainable 
approach without the controversy created about GMOs.
Argentina
Argentina was a pioneer country in the regulation of NBTs. In 2015, the Secretariat 
of Agriculture, Ganadería y Pesca (SAGyP) released the Resolution 173/15, which 
defines the assessment guidelines for NBT-derived crops. It is important to note that 
the resolution was drafted without the requirement of a list of specific technologies 
and is not restricted to the technical innovations available at the moment. As new 
breeding technologies are constantly published and patented, the inclusion of a 
specific list could compromise the speed of regulation of additional technological 
innovations.
The Comisión Nacional Asesora de Biotecnología Agropecuaria (Conabia) is 
the entity responsible for assessing, based on technical and scientific criteria, 
the potential environmental impact of the introduction of biotechnological 
crops in Argentine agriculture. The commission is recognized worldwide for its 
experience in the evaluation of dossiers, being considered as a reference center 
for the biosafety of GMOs by the Food and Agriculture Organization of the United 
Nations (FAO) (Ministerio de Agricultura, Ganadería y Pesca, 2019). Conabia has 
active participation in international debates related to biosafety and regulatory 
processes (USDA Foreign Agricultural Service, 2019). Therefore, Conabia is the body 
responsible for the evaluation and regulation of new breeding technologies, which 
guarantees compliance with the Resolution No. 173/15.
Chapter 5  Regulatory Framework of Genome Editing in Brazil and Worldwide 179
All products obtained by genome editing must be submitted to Conabia. The 
dossier can be submitted in two moments: after obtaining the final product or in 
the design phase of the creation process (project). In the design phase, inventors 
can consult Conabia to evaluate the expected product, determining whether the 
hypothetical product would be under GMO regulation or not. When the NBT-
derived product is obtained, technical data on the genetic modification must be 
submitted to ascertain whether the expected regulatory status remains the same 
as preliminary assessment.
Under the regulatory framework, the evaluation time is 60 days, and electronic 
forms are available for speedy evaluation. The main criteria taken into account are 
(1) the techniques used in the process; (2) the new combination of the generated 
genetic material; and (3) the absence of a transgene in the final product. A genetic 
modification is considered a new combination of genetic material when a stable 
and permanent insertion of a gene(s) or DNA sequence(s) into the plant's genome 
is present. In such cases, the final product will be regulated as GMOs (Resolution 
701/11 and 763/11). Also, even if a crop is exempt from GMO regulations but it 
has characteristics that pose a risk, it may undergo additional monitoring by the 
responsible authorities (Whelan; Lema, 2015).
Chile
In Chile, the Servicio Agrícola y Ganadero (SAG) is the entity responsible for 
regulating and monitoring the introduction, and propagation of genetically modified 
plants in the environment. An official SAG pronouncement in 2017 determined 
the regulatory procedure for crops obtained by NBTs, establishing a case-by-case 
approach, similar to Argentina. In general, crops developed using genome editing 
techniques that do not contain a new combination of genetic material are not 
subject to GMO regulations and are outside the scope of Resolution No. 1523/2001. 
For these purposes, a new combination of genetic material means a stable insertion 
of one or more genes or DNA sequences coding proteins, interference RNA, double-
stranded RNA, signal peptides, or regulatory sequences (Whelan; Lema, 2019).
Individuals or legal entities, research centers, or universities interested in 
introducing a new crop obtained by NBTs into the Chilean territory must forward a 
request form to the SAG's Agricultural Protection and Forest Division. The assessment 
is carried out within 20 working days. The request form must contain technical 
information including the name of the species, the variety/lineage, the description 
of the phenotype obtained, the company or institution that developed the material, 
the methodology, and the characteristics of the biotechnological technique used 
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with the indication of the modified DNA sequences. Also, the applicant must inform 
whether the material has precedent for authorization in another country and if so, 
the official documentation must be presented. The SAG decision is valid for an 
indefinite period but can be canceled if new scientific discoveries are available.
Colombia
In Colombia, the technical control of production and commercialization of 
agricultural products is under responsibility of the Instituto Colombiano Agropecuario 
(ICA). In 2018, the Resolution 29299 was issued, which establishes the consultation 
guidelines for products obtained by NBTs, on a case-by-case basis. The procedure 
for determining whether a cultivar developed by NBT corresponds to a GMO or to 
a conventional organism takes into account the presence or absence of exogenous 
genetic material. According to the document text, a cultivar is designated as a generic 
name to refer to varieties, plant lines, hybrids, and clones used as planting materials. 
Exogenous genetic material corresponds to a gene, set of genes, DNA sequences, 
that are part of a genetic construction and were stably introduced into the genome, 
through modern biotechnology techniques, overcoming the natural physiological 
reproduction barriers. In this context, if a cultivar does not have exogenous DNA 
sequences, it is not classified as a GMO. and is free from the regulation proposed in 
Decree 4525/2005.
The request for evaluation of a product obtained by NBTs must be sent to ICA, 
which analyzes the documentation within 30 days. For this, the applicant must be 
registered with the ICA as a seed producer, seed importer, or plant breeding research 
unit. The documentation in the application covers the following technical-scientific 
information: (1) the taxonomic classification of the species; (2) methodology and 
genetic constructs used, including all genetic elements and, in the case of DNA-free 
editing, the protein and RNA sequences used; (3) the description of the generated 
phenotype; (4) alternative methodologies for generating the phenotype; (5) 
molecular characterization of the genetic modifications present in the improved 
cultivar compared to the original genotype and absence of exogenous material.
Paraguay
In Latin America, Paraguay was the fifth country to present its position and 
regulation about products obtained through NBTs. Resolution 565/2019 was 
sanctioned by the Ministerio de Agricultura y Ganadería (MAG), the competent 
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national authority in the agricultural and forestry sector. According to the resolution, 
the products are evaluated, on a case-by-case basis, by the Comisión de Bioseguridad 
Agropecuaria y Forestal (Combio), upon submission of the prior consultation form 
for products obtained by NBTs.
The prior consultation form consists of six sections covering information of the 
applicant, the organism, molecular biology, the phenotype, authorizations, and 
references. In the Information section about the applicant, the legal representative 
and technical responsible for the application must also be presented. The Organism 
section includes the scientific name and a detailed taxonomic description of the 
species, including cultivar and lineage must be provided. The Molecular Biology 
section refers to a detailed description of the technique used, and the steps applied, 
a molecular description of the target nucleotide sequences and their functions 
in the organism before and after the application of the technique. If applicable, 
the genetic construction with the details of the genetic elements, the analysis of 
target sequences, and, in cases where an intermediate transgene was used, the 
evidence proving the absence of recombinant sequences must also be provided. 
In the Phenotype section, examples of products with a similar phenotype on the 
market, the analysis of the probability of occurrence of other effects besides the 
desired phenotype, the expected changes in the proposed uses of the organism, 
and changes in the management recommendations of the resulting organisms are 
requested. In the Authorizations section, indicate if the organism has already been 
authorized by the regulatory entity from another country and if so, provide the 
type of authorization. Finally, in the References section, copies of all publications 
mentioned in the form must be included. Based on the assessment of all these 
points, Combio will determine whether the organism is classified as genetically 
modified or not.
Regulation of genome editing in North America
Canada
Canada differs from other countries in approving a genetically modified 
organism (GMO), the regulatory approach is based exclusively on products, and not 
on the process or technique used to develop the new product (Ellens et al., 2019). 
The product or the plant with a new characteristic (PNT – a plant with a novel trait) 
needs to present modification that differs from the original variety to be analyzed by 
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regulatory agencies. A PNT is a plant in which a characteristic has been introduced 
intentionally, new to plants of the same species grown in Canada, with the potential 
to affect the usage and safety of the plant considering the environment and human 
health (Canada, 2019). This rule applies to both plants developed by classical 
breeding and genetically edited plants.
Products created or modified in Canada are regulated by several government 
agencies, including the Canadian Food Inspection Agency (CFIA), Health Canada, 
and Environment and Climate Change Canada (ECCC). The CFIA is responsible for 
plant regulation, animal feed, fertilizers, and veterinary products of biotechnological 
origin. The Plant Biosafety Office of CFIA is responsible for coordinating the safety 
assessment of new foods. Health Canada supervises food, medicine, and pest 
control products. The evaluations conducted by CFIA and Health Canada are based 
on scientific criteria and guidelines established by the World Health Organization 
(WHO), the Food and Agriculture Organization (FAO), and the Organization for 
Economic Cooperation and Development (OECD) (Dederer; Hamburger, 2019). 
ECCC operates on the regulation of all animal products of biotechnological origin 
not covered by another federal law and is based on the Canadian Environmental 
Protection Act, 1999 (CEPA).
In order to receive registration approval and be able to enter the Canadian 
market, a product with a new feature needs to undergo several tests carried out 
by technicians from CFIA and Health Canada.  These tests aim to corroborate the 
results already provided by the applicant. After reviewing all the data provided 
by the applicant coupled with the new tests, if all conditions are met, the product 
is accepted.
In Canada, when GM crops were being developed in the early 1990s, regulatory 
systems were also in development. Thus, the laws were already available to the 
needs of these crops. There is no specific law for plants genetically modified by NBTs 
or conventional breeding. The regulation is based on the product, which is released 
for consumption based on its safety assessment.
Four legislation acts are involved in the regulation of agricultural products. 
The Seed Act regulates stability, and environmental risk, for example, plant 
potential to become a weed and the impact of a plant or its products on non-
target species (Branch, 2019a). The Animal Feeding Act regulates risks related to 
toxicity, allergenicity, and digestibility (Branch, 2019b). The Food and Drug Act 
establishes the risk limits for toxicity, allergenicity, metabolism, and nutrition-
related to human consumption (Branch, 2020). In addition, CFIA applies the 
following guidelines to analyze herbicide-resistant varieties, regardless of the 
technology used to create a variety:
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• Directive 94-08: Assessment Criteria for Determining Environmental Safety of 
Plants with Novel Traits.
• Directive 95-03: Guidelines for the Assessment of Novel Feeds: Plant Sources. 
• Directive 96-13: Import Requirements for Plants with Novel Traits, including 
Transgenic Plants and their Viable Plant Parts.
• Directive 2000-07: Conducting Confined Research Field Trials of Plants with 
Novel Traits in Canada.
The International Service for the Acquisition of Agri-Biotech Applications 
(ISAAA) reported in 2017 that Canada planted an area of 13.12 million hectares with 
biotechnological crops, accounting for 7% of the world planted area. During the 
21 years of commercialization of GM plants, Canada made a profit of US$8 billion 
(ISAAA, 2017), and with the new cultivars that are expected to be incorporated, 
increased profits in the coming years. 
United States of America
In the United States of America, the regulation of crops produced through the 
use of genetic technologies is based on decades-old policies managed by various 
statutes and regulations, implemented by different federal government agencies 
(Dederer; Hamburger, 2019). American regulatory entities are the US Department of 
Agriculture (USDA), the Environmental Protection Agency (EPA), and the Food and 
Drug Administration (FDA). These federal agencies aim to ensure that genetically 
modified crops and their products are safe for health, the environment, and 
agriculture.
The regulatory policy for biotechnological products was established with 
the Biotechnology Regulatory Framework, published in 1986 (OSTP, 1986), and 
later updated in 1992. This document allows three conclusions that influence 
American biotechnology policy to this day: products are not necessarily different 
from conventional products; regulations should not focus on the process but the 
product, and regulatory jurisdiction must be based on use.
The Animal and Plant Health Inspection Service (APHIS) and the USDA 
Biotechnology Regulatory Service (BRS) are responsible for releasing field tests, 
interstate movement, and import of GM plants that may present some risk (Dederer; 
Hamburger, 2019). APHIS has released a new regulation, the Sustainable, Ecological, 
Consistent, Uniform, Responsible, Efficient Rule (SECURE Rule) (United States, 2020), 
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which aims to update and modernize the Plant Protection Act, removing outdated 
processes, and inserting biotechnological regulations (United States, 2020a).
The EPA regulates GM plants with pesticidal substances under the Federal 
Insecticides, Fungicides, and Rodenticides Act (FIFRA) (United States, 2020b) and 
pesticide residues in GE foods under the Food, Drug, and Cosmetics Act (FDCA) 
(United States, 1938).
The FDA regulates food safety under the FDCA. In the USA, new food developers 
are legally responsible for assessing food safety and complying with FDA regulations 
and statutes. And to ensure food safety, the FDA relies on legal provisions that 
prohibit adulteration, and incorrect food identification (Dederer; Hamburger, 2019). 
A food is considered adulterated if it has or contains one or more substances added 
that could be harmful to health or if the additive is not safe. Thus, if GM or processed 
foods do not show nutritional differences from conventional food, it is considered 
equivalent. According to the FDCA definition, substances that are “generally 
recognized as safe” (GRAS) are excluded from food additives. Due to new forms of 
breeding and gene editing, several discussions have pointed to possible changes in 
the regulations.
The American government has always encouraged the use of new technologies 
in agriculture as a way to increase its competitiveness (Bergeson, 2017) and, 
currently, the use of genome editing techniques in plants is on the rise. In 2019, the 
USA planted 75 Mha of transgenic crops, which corresponds to 40% of the world 
total, which was 190.4 Mha (ISAAA, 2019), and are the leaders in approving and 
cultivating genetically modified varieties. 
Regulation of genome editing in the European Union
The European Union (EU) has the strictest legislation in the world regarding 
the cultivation and consumption of GMOs in its territory with less than 0.1% of 
the global area is grown with GM crops Davison; Ammann, 2017). Only a single 
transgenic Bt event (MON810) is currently authorized for commercial cultivation in 
Spain and Portugal. However, the EU is a major importer of transgenic soybean and 
corn for animal feed (Dederer; Hamburger, 2019).
The EU regulatory concept strictly follows the “Precautionary Principle”, which 
considers that, if an action may cause irreversible public or environmental damage, 
in the absence of irrefutable scientific consensus, the burden of proof is on the 
side of those who intend to practice the act or action that may cause the damage. 
Different GM crops would be within this principle, since they were manipulated 
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in the laboratory, and would be different from the original crops. In the EU, the 
regulation banning GMOs is well established, however, with the advancement 
of genetics, especially the NBTs, the discussion on the use of biotechnology in 
agriculture is resuming.
The EU regulation on GMOs is based on Directive 2001/18/EC; Regulations (EC) 
No. 1829/2003 and No. 1830/2003; in Regulation (EC) No. 1946/2003; in Directive 
2009/41/EC and Directive (EU) 2015/412 (European Commission, 2020).
Directive 2001/18/EC regulates the assessment of environmental risks and 
the release of GMOs, as well as their commercialization (import, processing, and 
transformation) within the European bloc. The concept of GMOs for EU, according 
to this legal classification, is: “‘genetically modified organism (GMO)” means an 
organism, except for human beings, in which the genetic material has been altered 
in a way that does not occur naturally by mating and/or natural recombination”. 
This concept does not apply to human beings. According to Annexes 1A and 1B 
of that directive, genetic modifications without the use of recombinant DNA, and 
obtained by in vitro fertilization techniques, natural processes such as conjugation, 
transduction, transformation, polyploidy induction, classical mutagenesis 
(chemical mutagenesis and radiation), and protoplast fusion are excluded from the 
classification of GMOs.
Gene editing via CRISPR does not normally involve transgenics - the transfer of 
"genes" between species. However, on July 25, 2018, the EU Court of Justice (EUCJ) 
determined that all plants obtained through gene editing must be considered 
GMOs and fall within the scope of Directive 2001/18/EC (Ruffell, 2018). Among the 
justifications presented by the court, is the fact that the mutations caused by these 
techniques constitute changes made to the genetic material of the organism in an 
“unnatural” way and that the process uses recombinant DNA techniques. This is 
an aspect of EU regulation that differs from US and Canadian standards, based on 
product safety, regardless of the process used to obtain it (Friedrichs et al., 2019; 
Leone, 2019).
The precautionary principle for new approaches was used as a justification for 
the prohibition, aiming to avoid possible harmful effects to human, animal health, 
and the environment. Most requests for GMOs in the EU have been denied, and 
those approved have limited consent for 10 years (renewable), with mandatory 
monitoring after placing on the market (Schulman et al., 2020). The average approval 
time for food for human and animal consumption (excluding cultivation purposes) 
could take around 5 years (Zimny et al., 2019).
CRISPR technology in genomic plant editing186
Considering the European community's concern with GM food and animal feed, 
Regulation (EC) No. 1829/2003 restricts the unauthorized entry of GMOs into the 
EU and obliges suppliers of GM plants, and products to label food containing more 
than 0.9% of GMOs, informing the methods for its detection (Davison; Ammann, 
2017). Regulation (EC) 1830/2003 of the European Parliament and the EU Council 
also regulates the traceability and labeling of GM foods, to ensure that consumers 
are informed about the presence of GMOs and their products, to allow an informed 
choice of the product (Davison; Ammann, 2017). Besides Directive 2001/18/EC, 
which requires mandatory monitoring after the commercial release of GM products, 
Directive 2009/41/EC complements and requires EU-Member to send a report every 
three years, describing their experiences with the released product, informing 
risk assessment, accidents, an inspection of compliance control, consultation and 
information to the public, and waste disposal (European Commission, 2012). Besides 
these measures, through regulation (EC) No. 1946/2003, about transboundary 
movements of GMOs, it became mandatory to introduce protective measures in 
the border areas of the territory, to avoid possible contamination between non-GM 
and GM crops neighboring countries (European Commission, 2020).
Even with all these regulations, there were cases of release of the entry of GMOs 
into the European bloc, contrary to the opinion of several EU-Member. Faced with this 
setback, Directive (EU) 2015/412 of March 11 (which amended Directive 2001/18/
EC) emerged, which concerns the possibility for the Member States to restrict or 
prohibit the cultivation of GMOs in their territory using the “opt-out” clause, and the 
principle of subsidiarity (Davison; Ammann, 2017). Among the Member States that 
have chosen to completely restrict the entry of GMOs into their territory are Austria, 
the Walloon Region (Belgium), Bulgaria, Croatia, Cyprus, Denmark, France, Germany, 
Greece, Hungary, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, 
Slovenia, Northern Ireland, Wales, and Scotland (United Kingdom) (Friedrichs et al., 
2019). Plants edited by the new breeding techniques are considered GMOs by the 
European parliament and are therefore included in all EU GMO regulatory measures.
EU legislation that restricts GMOs and crops grown in Europe has significant 
economic impacts on the food sector, and agriculture. The EU seed market, for 
example, is estimated at €7 billion a year (Friedrichs et al., 2019). The impossibility of 
cultivating, and developing crops improved by modern biotechnology also causes 
the transfer of research investments outside the EU, impacting the research and 
innovation sector.
According to Brookes and Barfoott (2014), in the 17 years (before 2012) of 
the adoption of agricultural biotechnology by 17.3 million farmers, there was an 
economic benefit of US$ 116.6 billion, which increased to US$ 167.7 billion by 
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2015. GM crops generated a 37% reduction in the use of chemical pesticides, a 22% 
increase in agricultural production, and a 68% profit for farmers (Klümper; Qaim, 
2014). Similar or greater benefits can be achieved in the EU, through adherence 
to edited crops, besides the benefits of using green technology, including the 
European bloc in the competitive global commodities market. Among the EU's 
agricultural challenges is the sustainable production of food with fewer crop 
protection products, irrigation, grown in a smaller area, under constant climate 
change. These requirements show the need for new improved cultivars, leaving 
genome editing as a promising solution for the European market. However, the EU 
needs to harmonize its biotechnology legislation with other countries, mainly with 
the main food producers in the world.
Regulation of genome editing in Asia
China strictly regulates the import and production of GMOs, according to the 
regulations issued by the Chinese Ministry of Agriculture and Rural Affairs (MARA) 
in 2001, which predicts the administration of the security of agricultural GMOs. 
In 2018, through the National Bio-Safety Committee (NBC), MARA amended the 
regulations on safety assessment, import approval, and GMO labeling. The revised 
rules impose additional tests and studies in the country on biotechnological 
products. The Chinese government, as of 2016, created a 5-year support plan 
for research initiatives aimed at gene editing (Cohen, 2019). The purchase of 
Syngenta by state-owned ChemChina in 2017 reinforces China's interest in the 
field of technology for food production. Despite being one of the countries with 
the largest number of publications related to gene editing, the legislation classifies 
edited organisms as GMOs. MARA indicated in 2019 that new regulations are under 
development, to align China with other countries, as these regulations may provide 
a simplified regulatory process for genetically edited products in the future (United 
States, 2019).
In Japan, products edited using NBTs are evaluated on a case-by-case basis and 
need to be notified to the government, which requires technical information about 
the technique used and the genes targeted for modification. Modified organisms 
that contain exogenous DNA in their construction or are under the regulations for 
GMOs, as well as edited cultivars that might cross with an unedited cultivar, must 
be notified (Sato, 2020). Regulation is carried out by four Ministries: Ministry of 
Agriculture, Forestry and Fisheries; Ministry of Environment; Ministry of Education, 
Culture, Sports, Science and Technology; Ministry of Health, Labor and Welfare. In 
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addition, an independent commission, the Food Safety Commission (FSC), carries 
out the risk assessment of food and animal feed.
Recently, India issued preliminary rules for the regulation of edited products, 
requiring safety tests that prove the effectiveness of gene editing. Like many 
other countries, India adopts a position that evaluates the process used for editing 
instead of evaluating the final product. For SDN-1 technique regulation, extensive 
data demonstrating that the gene edition was successful, is required. When using 
SDN-2 for editing organisms, besides proving the effectiveness of the edition, field 
tests are necessary to prove the efficiency of the transformation. When inserting 
an exogenous DNA using the SDN-3 technique, the organism follows the same 
process as GMOs, which include tests for human and animal food safety, and risks 
to the environment. The responsibility for carrying out the evaluations lies with the 
Institutional Biosafety Committee, the Genetic Engineering Evaluation Committee, 
and the Genetic Engineering Review Committee (India, 2020).
Indonesia does not have specific regulations for the production of edited 
cultivars. All products from gene editing are evaluated as GMOs. The assessments 
and regulations are carried out based on the Protocol on Biosafety of the 
Convention on Biological Diversity, based on the Government Regulation No. 
21/2005. The responsibility for the initial assessment is under the responsibility 
of a non-departmental government agency. Subsequently, the analysis is sent to 
the Convention on Biological Diversity (CBD), a biosafety commission linked to the 
National Agency for Drug and Food Control (Badan POM). If the product meets the 
regulations stipulated by law, it is forwarded to the National Agency for the Control 
of Medicines and Food, and the notification is then reassessed by the biosafety 
committee, and released (Badan Pengawas Obat dan Makanan, 2012).
Regulation of genome editing in Oceania
Australia
Australia adopts a position that evaluates the process used for editing instead of 
evaluating the final product. Organisms resulting from a gene-editing process are 
regulated by the Gene Technology Regulator (GTR). GTR is responsible for regulating 
the production and release of GMOs, based on the standards described in the Gene 
Technology Regulations 2001, made under the Genetic Technology Act 2000.
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With the NBTs, such as CRISPR, transcription activator-like effector nucleases 
(TALENs), and Zinc-finger nucleases (ZFNs), the regulatory process needed to be 
adapted. In 2019, the Gene Technology Amendment (2019 Measures No. 1) was 
created. The NBT-derived product is systematically reviewed to determine whether 
it should or not be classified as a low-risk transformation or transformation exempt 
from notification. The regulations are described in sections 140 and 141 of the 
amendment. Item 4 of Annex 1 of the amendment states that organisms modified 
with NBTs are not considered GMOs since no nucleic acid is present. SDN-1 is not 
regulated due to similarity to traditional mutagenesis techniques. SDN-2 and SDN-3 
may or may not insert an exogenous DNA into the organism's genome with stable 
or transient character (Eckerstorfer et al., 2019).
As the regulation of organisms modified by NBTs is the responsibility of the 
GTR, in Australia and New Zealand food is regulated by a joint system, the Food 
Standards Australia New Zealand (FSANZ). FSANZ is responsible to develop and 
define pre-market regulations, such as food labeling from gene editing (Food 
Standards Australia New Zealand, 2019).
New Zealand
New Zealand, unlike Australia, considers all gene-editing techniques as GMOs. The 
country adopts a position of caution and observance of the regulations stipulated 
globally, to adapt its system over time, according to international developments 
(Fritsche et al., 2018).
Research involving genetically edited plants is supervised by the Environmental 
Protection Authority (EPA), which is responsible for supervising the development, 
and release of GMOs under the Hazardous Substances and New Organisms (HSNO) 
Act 1996. All gene-editing techniques are regulated, even when exogenous genes 
are not incorporated (New Zealand, 2019).
Harmonization of global legislation  
on genome editing in plants
In the Brazilian evaluation (similar to what to other countries in the Americas, 
Japan, Australia, Israel, among others), mutations produced by SDN-1 are not 
classified as GMO in the light of Biosafety Law. The same occurs with products 
obtained by classical improvement, or by mutations induced by various external 
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factors, such as exposure to UV light, ionizing radiation, chemical substances, or 
even errors during DNA replication. The accumulated knowledge on the genome 
of different species has allowed a more precise modification when compared 
to traditional mutation systems as radiation or chemical agents used in the 
development of commercial varieties for decades.
Genome editing systems type SDN-2 may or may not be classified as GMOs 
under the Brazilian legislation and most countries in the Americas, in case-by-
case analyses. SDN-2 is similar to natural mutagenesis, altering small portions of 
genomic DNA, as occurs in genetic improvement programs, or changes caused 
by chemicals/radiation, or even in the natural differentiation of germplasm from a 
species collected in different locations. The main differentiating factor in considering 
products obtained by the SDN-2 system as GMOs has been the presence of DNA of 
another species in the final product.
SDN-3 system, on the other hand, due to the complexity of the introduced 
genetic elements, normally is classified as GMOs, always depending on a case-by-
case analysis, and the origin of the DNA used.
Unlike the Brazilian Biosafety Law, which excludes mutagenesis from the scope 
of GMOs, the decision of the Court of Justice of the European Union on the subject 
(case C-528/16, of July 25, 2018) established that Directive 2001/18/CE, on GMO risk 
analysis, applies to products obtained by "new mutagenesis techniques", that is, 
SDN systems.
The European scientific community, as well as companies that develop products 
with biotechnological techniques, has provoked a discussion with European 
regulatory agencies, aiming to review this decision and align European legislation 
with the rest of the world. In this sense, the European Food Safety Authority 
(EFSA), in a public consultation carried out in May 2020, evaluated the possibility 
of products obtained by SDN-1 and SDN-2 systems having a different risk analysis 
than what currently occurs in the European Union in the relation to GMOs. In a first 
discussion panel, EFSA had concluded that risk assessment methodologies on SDN-
3 system could be simplified compared to what is done with GMOs, since in the 
SDN-3 system the introgression in the of gene sequences into the genome occurs in 
a targeted manner and defined place, unlike processes with traditional transgenics, 
in which insertions in the genome are random.
In a second discussion panel, the EFSA also decided that the conclusions of the 
first panel would be partially applicable to the SDN-1 and SDN-2 systems. Since 
SDN-1/SDN-2 approaches aim to modify an endogenous DNA sequence whose 
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final product does not contain exogenous DNA. Therefore, these products would 
not present any of the potential risks related to the insertion of a transgene.
Several countries, including Brazil, understand that the introduction of variability 
in species of economic importance could help achieve important sustainability 
goals, healthier foods, less use of chemical pesticides, contributing to a healthier 
environment, and mitigation of problems caused by global climate change, among 
other possibilities. However, innovations in genetics must take into account the 
basic principles of biosafety.
Legislation should not stop technological development and the possibility of 
generating biotechnology-based should not be restricted to a few institutions and 
companies, as occurred in the case of transgenics, considering the expensive and 
time-consuming approval processes created by each country. If products resulting 
from targeted mutagenesis, mainly SDN-1 and SDN-2 systems, are subject to the 
same risk assessment requirements as traditional GMOs/SDN-3, technological 
development may be restricted to few large companies, limiting competition and 
market share.
Brazil, Argentina, Canada, Chile, Colombia, USA are among the first to have 
legislation that regulates the use of gene editing techniques. In these countries, the 
increase in number, type, and size of institutions/companies developing products 
of interest to society, is clear. Moreover, there is a significant increase in the number 
of species worked with NBTs. In GMOs, investment was only viable for major 
commodities, such as soybeans, corn, and cotton, among the main ones.
As SDN-1 and SDN-2 systems simulate/imitate mechanisms of genetic variability 
induction that occur constantly and frequently in nature, their detection in genome-
edited products is practically impossible. The European Union, in the report 
“Detection of food and plant foods obtained by new mutagenesis techniques” 
(European Commission, 2019), recognizes that products whose genome has been 
edited may be indistinguishable from products altered by natural processes or by 
conventional reproductive techniques.
Brazil, in alignment with the national and international scientific community, and 
with the legislation of several countries, many of which are commercial partners, 
understands the importance of harmonizing the biosafety laws of food exporting 
and importing countries. Biosafety laws should reflect and welcome technological 
progress, maintaining food quality and safety but also allowing diversification of 
participants in the production chain. Products generated by genome editing, 
mainly by the SDN-1 and SDN-2 systems, should not be subject to risk analysis 
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requirements like GMOs if they could also be obtained by conventional methods or 
spontaneous processes in nature.
Harmonization of regulatory rules also allows creating legal assurance for 
developers in each country, avoiding individual national/regional rules for products 
resulting from conventional random mutagenesis or the use of SDN systems. Also, it 
prevents two indistinguishable products from being regulated in two different ways.
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